Patent · US Active

Hepatocyte growth factor (HGF) binding antibody

US7649083B2 · kind B2 · utility

19Cited by

6References

9Claims

0Family size

Assignees

AVEO Pharmaceuticals, Inc. · US
XOMA TECHNOLOGY LTD. · US

Inventors

William M. Winston, Jr. · Marlborough, US
S. Kirk Wright · Waltham, US
May Han · Brookline, US
Lyne Breault · Brookline, US
Jie Lin · Dedham, US
Bijan Etemad-Gilbertson · Brookline, US
Christine Knuehl · Natick, US
Jeno Gyuris · Lincoln, US
Arnold Horwitz · San Leandro, US

Key dates

Filing date	Jun 1, 2007
Grant date	Jan 19, 2010
Priority date	—
Expiry date	Jan 15, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.